Cytokinetics, Inc.
624 articles about Cytokinetics, Inc.
-
Cytokinetics to Participate in Upcoming Investor Conferences - June 02, 2022
6/2/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 01, 2022
6/1/2022
Cytokinetics, Incorporated announced that on May 31, 2022 it granted stock options to purchase an aggregate of 179,100 shares of common stock to 23 new employees, whose employment commenced in May 2022, as a material inducement to their employment.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Cytokinetics filed with the SEC reporting that the FDA planned to hold an advisory committee meeting to review its New Drug Application (NDA) for omecamtiv mecarbil.
-
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference
5/17/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present virtually at the 2022 H.C. Wainwright Global Life Sciences Conference taking place May 23-26, 2022.
-
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv MecarbilFDA Plans to Convene Advisory Committee Meeting
5/17/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the Company recently participated in a mid-cycle communication meeting with the U.S. Food & Drug Administration (FDA) and was informed that the Agency plans to convene an Advisory Committee meeting for the New Drug Application (NDA) for omecamtiv mecarbil.
-
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress
5/16/2022
Cytokinetics, Incorporated announced three Late-Breaking Science presentations at Heart Failure 2022, an International Congress of the European Society of Cardiology taking place online and in Madrid, Spain from May 21, 2022 – May 24, 2022.
-
Cytokinetics Reports First Quarter 2022 Financial Results
5/4/2022
Cytokinetics, Incorporated reported financial results for the first quarter of 2022.
-
Cytokinetics to Announce First Quarter Results on May 4, 2022
4/20/2022
Cytokinetics, Incorporated announced that it is scheduled to report first quarter results on May 4, 2022 at 4:00 PM Eastern Time.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Cytokinetics Announces Changes to Board of Directors
4/8/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced changes to its Board of Directors. L. Patrick Gage, Ph.D., Chairman of the Board of Directors since March 2010, will resign from the Board effective April 8, 2022.
-
Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference
4/6/2022
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 11:00 AM ET.
-
The 71st annual American College of Cardiology's Scientific Session saw several wins over the weekend, led by some of the life sciences industries' largest companies.
-
Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
4/3/2022
Cytokinetics, Incorporated announced that the full results from METEORIC-HF, a Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, were presented by Michael Felker, M.D., Professor of Medicine, Duke Clinical Research Institute, at the American College of Cardiology 71st Annual Scientific Session.
-
Cytokinetics Announces Results From Cohort 3 of Redwood-HCM Presented at American College of Cardiology 71st Annual Scientific Session
4/2/2022
Cytokinetics, Incorporated announced that the full results from Cohort 3 of REDWOOD-HCM, the Phase 2 clinical trial of aficamten in patients with obstructive hypertrophic cardiomyopathy, were presented in a Moderated Poster Session by Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Assistant Professor of Medicine, University of Pennsylvania, at the American College of Cardiology 71st Annual Scientific Session.
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
Cytokinetics, Incorporated announced that on March 31, 2022 it granted stock options to purchase an aggregate of 165,600 shares of common stock to eighteen new employees, whose employment commenced in March 2022, as a material inducement to their employment.
-
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo
3/24/2022
Cytokinetics, Incorporated announced four presentations at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in Washington, D.C. from April 2, 2022 - April 4, 2022.
-
Cytokinetics to Participate in Upcoming Investor Conferences in March 2022
3/8/2022
Cytokinetics Inc. announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 11:45 am ET at the Loews Miami Beach Hotel in Miami Beach.
-
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
-
Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to EnrollmentCohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy
3/2/2022
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM.